Research and Development: Comparing Key Metrics for Pfizer Inc. and Celldex Therapeutics, Inc.

R&D Spending Trends: Pfizer vs. Celldex Over a Decade

__timestampCelldex Therapeutics, Inc.Pfizer Inc.
Wednesday, January 1, 20141043810008393000000
Thursday, January 1, 20151001710007690000000
Friday, January 1, 20161027260007872000000
Sunday, January 1, 2017961710007657000000
Monday, January 1, 2018664490008006000000
Tuesday, January 1, 2019426720008650000000
Wednesday, January 1, 2020425340009405000000
Friday, January 1, 20215331100013829000000
Saturday, January 1, 20228225800011428000000
Sunday, January 1, 202311801100010679000000
Monday, January 1, 202410930000000
Loading chart...

Unleashing insights

A Decade of Innovation: R&D Spending in the Pharmaceutical Industry

In the ever-evolving landscape of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Pfizer Inc. and Celldex Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. Pfizer, a global giant, consistently allocated substantial resources, peaking in 2021 with a 38% increase from 2014. This commitment underscores Pfizer's strategy to maintain its leadership in drug development. In contrast, Celldex, a smaller biotech firm, exhibited a more volatile R&D expenditure pattern, with a notable 64% drop from 2014 to 2019, followed by a resurgence in 2023. This fluctuation reflects the challenges and opportunities faced by smaller firms in navigating the competitive biotech sector. As the industry continues to innovate, understanding these spending trends offers valuable insights into the strategic priorities of pharmaceutical companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025